Clinical trial · Observational
Spanish Registry of Esophagogastric Cancer
AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy, anti-targeted agents and immunotherapy | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- Resectable non-advanced cancer
- interventionNames
- Procedure: Surgery
- Drug: Chemotherapy, anti-targeted agents and immunotherapy
- Radiation: Radiotherapy
- label
- Cohort 2
- description
- Unresectable advanced cancer
- interventionNames
- Procedure: Surgery
- Drug: Chemotherapy, anti-targeted agents and immunotherapy
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Diagnostic and therapeutic approach
- timeFrame
- Up to 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown). * Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause. Exclusion Criteria: * A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
References
Publications (0)
Data not yet available